Akari Therapeutics (AKTX) Prepaid Assets (2014 - 2026)
Akari Therapeutics (AKTX) reported Prepaid Assets of $30000.0 for Q1 2026, down 95.22% on a YoY basis from $627000.0 in Q1 2025, and down 83.78% sequentially from $185000.0 in Q4 2025.
Akari Therapeutics (AKTX) Prepaid Assets (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 13 years of Prepaid Assets data on file, last reported at $30000.0 in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets fell 95.22% year-over-year to $30000.0; the trailing twelve-month figure through Mar 2026 stood at $30000.0 (down 95.22% YoY), and the FY2025 full-year result was $185000.0, up 101.09% from the prior year.
- Prepaid Assets eased to $30000.0 in Q1 2026, from $185000.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $627000.0 in Q1 2025 to a low of $30000.0 in Q1 2026.
- A 5-year average of $228545.5 and a median of $185000.0 in 2025 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets jumped 375.53% in 2025 and tumbled 95.22% in 2026, its largest moves.
- Tracing AKTX's Prepaid Assets over 5 years: stood at $465000.0 in 2022, then tumbled by 57.63% to $197000.0 in 2023, then tumbled by 53.3% to $92000.0 in 2024, then soared by 101.09% to $185000.0 in 2025, then slumped by 83.78% to $30000.0 in 2026.
- Business Quant data shows AKTX's Prepaid Assets at $30000.0 in Q1 2026, $185000.0 in Q4 2025, and $53000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 185,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 627,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Mar 31, 2024 | 232,000.00 |
| Dec 31, 2023 | 197,000.00 |
| Dec 31, 2022 | 465,000.00 |
| Dec 31, 2021 | 2.17 Mn |
| Dec 31, 2020 | 229,200.00 |
| Sep 30, 2020 | 1.35 Mn |
| Jun 30, 2020 | 1.68 Mn |
| Mar 31, 2020 | 1.83 Mn |
| Dec 31, 2019 | 712,975.00 |
| Sep 30, 2019 | 1.06 Mn |
| Jun 30, 2019 | 1.75 Mn |
| Mar 31, 2019 | 1.89 Mn |